inclusion criteria: * adults (greater than or equal to \[\>=\] 18 years) with sars-cov-2 infection. * participants with symptoms and/or signs consistent with covid-19, requiring treatment. * a score of grade 3 to 5 on the 9-point ordinal scale. in india; only participants with a score of grade 4 or 5 will be enrolled. * a) male participants: * a male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. b) female participants: * a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: 1. not a woman of childbearing potential. or 2. a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. * women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded). * ability to provide informed consent signed by the study participant or legally authorized representative.

inclusion criteria: * adults (greater than or equal to \[\>=\] 18 years) with sars-cov-2 infection. * participants with symptoms and/or signs consistent with covid-19, requiring treatment. * a score of grade 3 to 5 on the 9-point ordinal scale. in india; only participants with a score of grade 4 or 5 will be enrolled. * a) male participants: * a male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. b) female participants: * a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: 1. not a woman of childbearing potential. or 2. a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. * women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded). * ability to provide informed consent signed by the study participant or legally authorized representative.

inclusion criteria: adults (greater than or equal to [>=] 18 years) with sars-cov-2 infection. participants with symptoms and/or signs consistent with covid-19, requiring treatment. a score of grade 3 to 5 on the 9-point ordinal scale. in india; only participants with a score of grade 4 or 5 will be enrolled. a) male participants: a male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. b) female participants: a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: not a woman of childbearing potential. or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded). ability to provide informed consent signed by the study participant or legally authorized representative.

inclusion criteria: adults (greater than or equal to [>=] 18 years) with sars-cov-2 infection. participants with symptoms and/or signs consistent with covid-19, requiring treatment. a score of grade 3 to 5 on the 9-point ordinal scale. in india; only participants with a score of grade 4 or 5 will be enrolled. a) male participants: a male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. b) female participants: a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: not a woman of childbearing potential. or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded). ability to provide informed consent signed by the study participant or legally authorized representative.

inclusion criteria: - adults (greater than or equal to [>=] 18 years) with sars-cov-2 infection. - participants with symptoms and/or signs consistent with covid-19, requiring treatment. - a score of grade 3 to 5 on the 9-point ordinal scale. in india; only participants with a score of grade 4 or 5 will be enrolled. - a) male participants: - a male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. b) female participants: - a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: 1. not a woman of childbearing potential. or 2. a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. - women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded). - ability to provide informed consent signed by the study participant or legally authorized representative.

inclusion criteria: - adults (greater than or equal to [>=] 18 years) with sars-cov-2 infection. - participants with symptoms and/or signs consistent with covid-19, requiring treatment. - a score of grade 3 to 5 on the 9-point ordinal scale. in india; only participants with a score of grade 4 or 5 will be enrolled. - a) male participants: - a male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. b) female participants: - a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: 1. not a woman of childbearing potential. or 2. a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. - women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded). - ability to provide informed consent signed by the study participant or legally authorized representative.